<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="223058">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179010</url>
  </required_header>
  <id_info>
    <org_study_id>030371</org_study_id>
    <nct_id>NCT00179010</nct_id>
  </id_info>
  <brief_title>AMP as a Better Delivery System of Adenosine</brief_title>
  <official_title>Use of AMP to Improve Tissue Delivery of Adenosine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenosine and AMP are substances normally present in the body. Adenosine is also given for
      the treatment of some heart rhythm problems and may be used to reduce heart damage during
      heart attacks. The problem in using adenosine is that it is taken up by cells and,
      therefore, very little of the adenosine we give by vein or in the artery actually reaches
      the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive
      by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will
      increase levels of adenosine in tissue. To see if this is true, we will give either
      adenosine or AMP into the forearm artery while we measure how much adenosine reaches the
      forearm tissue.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    In process of renewing IND for AMP
  </why_stopped>
  <start_date>October 2003</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial adenosine levels</measure>
    <time_frame>Duration of ia infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Forearm blood flow</measure>
    <time_frame>Duration of ia infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrarterial infusion of adenosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrarterial infusion of AMP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine Mono Phosphate (AMP)</intervention_name>
    <description>Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age 18-65

          -  Non smokers

        Exclusion Criteria:

          -  Smokers

          -  Any chronic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 2, 2015</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Adenosine</keyword>
  <keyword>AMP</keyword>
  <keyword>Microdialysis</keyword>
  <keyword>Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
